 | | Vol. 12.30 – 6 August, 2020 |
| |
|
|
| Investigators integrated data derived from ChIRP-Seq, ChIP-Seq as well as RNA-Seq in a comprehensive analysis and selected a group of bona fide direct transcriptional targets of EPR. Among them, they identified a subset of EPR targets whose expression was controlled by TGF-β with one of them-Arrdc3-being able to modulate epithelial to mesenchymal transition.
[Nucleic Acids Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated mammary epithelial cell phenotypes and metabolic profiles on animal breast extracellular matrix-derived tissue matrix gel, Col I, and Matrigel. Atomic force microscopy, fluorescence microscopy, acini formation assay, differentiation experiments, spatial migration/invasion assays, proliferation assay, and nuclear magnetic resonance spectroscopy were used to examine biological phenotypes and metabolic changes.
[Breast Cancer Research] |
|
|
|
| Researchers showed that AUF1 induced epithelial-to-mesenchymal transition and stemness in breast epithelial cells via stabilization of the SNAIL1 and TWIST1 mRNAs, and their consequent upregulation.
[Oncogenesis] |
|
|
|
| The authors defined the differential responses to trametinib in subpopulations of a clinically-relevant in vitro model of TNBC, and identified both adaptive and acquired elements that contribute to the emergence of drug resistance mediated by increased expression of CXCR7 and amplification of KRAS.
[Molecular Cancer Research] |
|
|
|
| Investigators found that by activating PRMT1, irradiation triggered a BRCA1-dependent program that resulted in efficient DNA repair and inhibition of apoptosis. Depletion of PRMT1 in irradiated cells resulted in a switch of BRCA1 functions from repair and survival in the nucleus to activation of cell death signals in the cytoplasm.
[Scientific Reports] |
|
|
|
| To better define the effects of oxidative stress, in vitro experiments were conducted on 4T1 and splenic mononuclear cells under hypoxic and normoxic conditions. Hydrogen peroxide was used as an reactive oxygen species source alone or in combination with hyaluronic acid.
[Journal of Cellular Physiology] |
|
|
|
| Carbon dot showed selective cytotoxicity against MCF7 breast cancer cells with the IC50 of 10 μg/ml while carbon dot based silver nanoparticles demonstrated synergistic effect on cytotoxicity.
[International Journal of Biological Macromolecules] |
|
|
|
| The nanocomplexes formed by metallodendrimers and different siRNA were examined for their zeta potential and size, and by transmission electron microscopy, fluorescence polarisation, circular dichroism, and electrophoresis. The internalisation of dendriplexes was estimated by flow cytometry and confocal microscopy in a human breast cancer cell line, following the ability of these metallodendrimers to deliver the siRNA into the cell.
[Pharmaceutics] |
|
|
|
| Researchers evaluated the effects and mechanisms of rosmarinic acid (RA) in two racially different TNBC cell lines. Results obtained showed that RA significantly caused cytotoxic and antiproliferative effects in both cell lines in a dose- and time-dependent manner. RA induced cell cycle arrest-related apoptosis and altered the expression of many apoptosis-involved genes differently.
[European Journal of Pharmacology] |
|
|
|
|
| The authors summarize recent literature regarding molecules and pathways and reviewed the effects of cancer stem cell biology during the formation of brain metastasis in triple-negative breast cancer.
[Cancers] |
|
|
|
|
| Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in Phase I clinical development for non-small cell lung cancer and TNBC.
[Daiichi Sankyo Ltd.] |
|
|
|
| Merck announced that the FDA has accepted two new supplemental Biologics License Applications for KEYTRUDA, Merck’s anti-PD-1 therapy.
[Merck] |
|
|
|
|
| October 12 – October 14
Paris, France |
|
|
|
|
|
| | University of Miami, Sylvester Comprehensive Cancer Center – Miami, Florida, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Mayo Clinic – Rochester, Minnesota, United States |
|
|
|
| | University of Texas-Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Georgetown University Medical Center – Washington, District of Columbia, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
